At the news
? NEUTRALIMPACT 2/10 8-K filed Nov 4, 2026 at 09:25 ET
Cencora filed an 8-K to disclose a restructuring of its operating model and a new reportable segment structure effective Q1 FY2027. The filing includes unaudited revised segment revenue and operating income data for FY2025 and FY2026 under the new segments: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. This is a routine disclosure of a structural change with no new financial guidance or material impact on overall results.
- Cencora restructured its operating model and reorganized business components within U.S. Healthcare Solutions and International Healthcare Solutions reportable segments.
- New reporting structure effective Q1 FY2027: Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other.
- Other segment includes businesses under strategic review: MWI Animal Health, Profarma, and other components of PharmaLex.
- FY2026 total revenue was $337.4 billion, up 5.0% from FY2025 total revenue of $321.3 billion.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access